Phase I Randomized, Double-Blind, Placebo-Controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1

Trial Profile

Phase I Randomized, Double-Blind, Placebo-Controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Resiquimod (Primary) ; Cancer vaccine NY-ESO-1; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jan 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 27 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015, according to the the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top